Table 2.
Clinical characteristics of the study cohort (n = 232)
| Clinical characteristics | Irbesartan/HCTZ (n = 69) | Valsartan/HCTZ (n = 163) | All (n = 232) | p value |
|---|---|---|---|---|
| Diabetes mellitus | 43 (62) | 61 (37) | 104 (45) | <0.001 |
| Ischemic heart disease | 14 (20) | 24 (15) | 38 (16) | 0.295 |
| Obesity | 7 (10) | 9 (6) | 16 (7) | 0.204 |
| Nephropathy | 8 (12) | 7 (4) | 15 (6.5) | 0.039 |
| Myocardial infarction | 1 (1.5) | 8 (4.9) | 9 (3.9) | 0.287 |
| Chronic heart failure | 1 (1.5) | 4 (4.5) | 5 (2.2) | 1.000 |
| Stroke | 1 (1.5) | 3 (1.8) | 4 (1.7) | 1.000 |
| Atrial fibrillation | 2 (2.9) | 2 (1.2) | 4 (1.7) | 0.584 |
| Anemia | 1 (1.5) | 2 (1.2) | 3 (1.3) | 1.000 |
| Retinopathy | 0 (0) | 1 (0.6) | 1 (0.4) | 1.000 |
| Deep vein thrombosis | 0 (0) | 1 (0.6) | 1 (0.4) | 1.000 |
| 78 | 122 | 200 | ||
Figures in parentheses indicate column percentages.
They might not add up to 100s% because some patients had more than one comorbidity.